[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:digestive-system-neuroendocrine-tumor":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":137,"states":146},"Digestive System Neuroendocrine Tumor",20,18,[8,16,23,30,37,43,50,56,62,68,74,81,87,93,99,105,111,117,123,130],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05477576","Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy",[12],"Phase 3","RECRUITING","2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.713577Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04086485","Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:09.641312Z","2026-05-05T02:43:29.651483Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07150546","Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.",[27],"Phase 1","2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.200887Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06395402","177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry",[34],"Phase 2","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.074931Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT04609592","Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery",[27],"2026-08-03T01:59:18.089574Z","2026-05-05T02:43:28.703397Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":48,"content_modified":49},"NCT06016855","Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors",[47],"Phase 4","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.860078Z",{"nct_id":51,"title":52,"phases":53,"status":13,"updated_at":54,"content_modified":55},"NCT05773274","Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial",[34],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.798127Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT06784752","Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",[12],"2026-08-26T02:15:14.574786Z","2026-05-05T02:35:31.867759Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT06427798","Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma\u002FParaganglioma Previously Treated With Systemic Targeted Radioligand Therapy",[20],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.752853Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT07165132","Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.",[27],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:27.257230Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":79,"content_modified":80},"NCT06943755","Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors",[78],"Phase 2\u002FPhase 3","2026-08-26T02:19:18.331180Z","2026-05-05T02:35:31.629898Z",{"nct_id":82,"title":83,"phases":84,"status":13,"updated_at":85,"content_modified":86},"NCT07174583","A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer",[20],"2026-08-26T02:16:21.385056Z","2026-07-19T19:36:05.070754Z",{"nct_id":88,"title":89,"phases":90,"status":13,"updated_at":91,"content_modified":92},"NCT05636618","Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors",[20],"2026-08-26T02:17:03.534765Z","2026-07-05T05:32:16.808808Z",{"nct_id":94,"title":95,"phases":96,"status":13,"updated_at":97,"content_modified":98},"NCT06479811","[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma\u002FParagangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers",[27],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.023362Z",{"nct_id":100,"title":101,"phases":102,"status":13,"updated_at":103,"content_modified":104},"NCT07635316","A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients",[],"2026-08-26T02:19:00.742020Z","2026-07-19T19:36:05.143202Z",{"nct_id":106,"title":107,"phases":108,"status":13,"updated_at":109,"content_modified":110},"NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.233960Z",{"nct_id":112,"title":113,"phases":114,"status":13,"updated_at":115,"content_modified":116},"NCT07563855","An Open Label Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes",[],"2026-08-26T02:15:44.309045Z","2026-05-13T02:55:06.728120Z",{"nct_id":118,"title":119,"phases":120,"status":13,"updated_at":121,"content_modified":122},"NCT06263088","EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.",[],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:27.634026Z",{"nct_id":124,"title":125,"phases":126,"status":127,"updated_at":128,"content_modified":129},"NCT02270567","RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide",[],"ENROLLING_BY_INVITATION","2026-08-26T02:17:05.997056Z","2026-06-16T05:54:07.950523Z",{"nct_id":131,"title":132,"phases":133,"status":134,"updated_at":135,"content_modified":136},"NCT05988918","Multicenter Trial of ESK981 in Patients With Select Solid Tumors",[34],"ACTIVE_NOT_RECRUITING","2026-08-03T02:02:51.511154Z","2026-05-05T02:43:29.366306Z",[138,142],{"biomarker":139,"count":140,"slug":141},"Somatostatin Receptor",12,"somatostatin-receptor",{"biomarker":143,"count":144,"slug":145},"MKI67 Gene",4,"mki67-gene",[147,151,154,158,161,164,168,171,174,177,180,183,186,189,192,195,198,202,205,208,211,214,217],{"state":148,"count":149,"slug":150},"Michigan",7,"michigan",{"state":152,"count":149,"slug":153},"Tennessee","tennessee",{"state":155,"count":156,"slug":157},"Florida",6,"florida",{"state":159,"count":156,"slug":160},"Kentucky","kentucky",{"state":162,"count":156,"slug":163},"Ohio","ohio",{"state":165,"count":166,"slug":167},"Iowa",5,"iowa",{"state":169,"count":166,"slug":170},"Maryland","maryland",{"state":172,"count":166,"slug":173},"New York","new-york",{"state":175,"count":166,"slug":176},"Texas","texas",{"state":178,"count":166,"slug":179},"Washington","washington",{"state":181,"count":144,"slug":182},"Arizona","arizona",{"state":184,"count":144,"slug":185},"California","california",{"state":187,"count":144,"slug":188},"Minnesota","minnesota",{"state":190,"count":144,"slug":191},"Missouri","missouri",{"state":193,"count":144,"slug":194},"Utah","utah",{"state":196,"count":144,"slug":197},"Virginia","virginia",{"state":199,"count":200,"slug":201},"Colorado",3,"colorado",{"state":203,"count":200,"slug":204},"Connecticut","connecticut",{"state":206,"count":200,"slug":207},"Georgia","georgia",{"state":209,"count":200,"slug":210},"Nebraska","nebraska",{"state":212,"count":200,"slug":213},"North Carolina","north-carolina",{"state":215,"count":200,"slug":216},"Pennsylvania","pennsylvania",{"state":218,"count":200,"slug":219},"Wisconsin","wisconsin"]